← Back to Search

Cancer Vaccine

Candin treatment for Common Warts

Phase 3
Recruiting
Research Sponsored by Nielsen BioSciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 27 weeks
Awards & highlights

Study Summary

This trial aims to see if the treatment with Candin is more effective in clearing common warts compared to a placebo. Participants will receive injections every two weeks until the wart is cleared and will be followed

Who is the study for?
This trial is for healthy individuals aged 12 and older who have between 3 to 20 common warts. Participants must be willing to use contraception during the study.Check my eligibility
What is being tested?
The trial tests if Candin, an intradermal solution, is more effective at clearing common warts than a placebo. Patients will receive injections in one wart every two weeks until it clears and will return after 12 weeks post-clearance for follow-up.See study design
What are the potential side effects?
Potential side effects of Candin may include skin reactions at the injection site, such as redness, itching or swelling. Other general side effects are not detailed but could resemble those typical of dermatological treatments.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~twelve weeks after last injection
This trial's timeline: 3 weeks for screening, Varies for treatment, and twelve weeks after last injection for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with complete resolution of the treatment wart
Secondary outcome measures
Number of participants with clinical clearance of all measured warts
Number of participants with clinical clearance of at least 50% of all measured warts
Time to clinical clearance of all measured warts
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Candin treatmentExperimental Treatment1 Intervention
Candida albicans Skin Test Antigen for Cellular Hypersensitivity will be administered as a 0.5 mL injection at the region of the interdigitated base of the treatment wart (epidermal/dermal junction) every 2 weeks for up to 10 injections
Group II: PlaceboPlacebo Group1 Intervention
Matching placebo (sterile saline) will be administered as a 0.5 mL injection at the region of the interdigitated base of the treatment wart (epidermal/dermal junction) every 2 weeks for up to 10 injections

Find a Location

Who is running the clinical trial?

Nielsen BioSciences, Inc.Lead Sponsor
4 Previous Clinical Trials
445 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current number of individuals involved in this medical study?

"Indeed, as per clinicaltrials.gov, this medical investigation is actively seeking volunteers. The trial was uploaded on March 5th, 2024 and most recently revised on March 15th, 2024. Enrollment of approximately 330 participants will be carried out across 18 diverse sites."

Answered by AI

What is the overall safety profile of Candin therapy for individuals undergoing treatment?

"Based on our evaluation, the safety rating for Candin therapy is graded as 3 due to it being a Phase 3 trial. This signifies existing efficacy data along with extensive safety data from multiple evaluations."

Answered by AI

Are participants currently being enrolled in this trial?

"As per clinicaltrials.gov, this investigation is actively pursuing potential candidates. It was initially shared on March 5th, 2024 and recently revised on March 15th of the same year."

Answered by AI

How numerous are the locations conducting this investigation within our city?

"As of now, patient recruitment is ongoing at 18 different sites. These sites are situated in Bryant, Brighton, Fort Smith, and various other locations. It is advisable to choose a site nearest to you to reduce travel requirements during your potential participation."

Answered by AI

Who else is applying?

What site did they apply to?
Johnson Dermatology
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Candin for the Treatment of Common Warts
2024. "Candin for the Treatment of Common Warts". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05889845.
~220 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top